Halozyme Therapeutics Inc (HALO)
Quick ratio
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Cash | US$ in thousands | 115,850 | 118,370 | 234,195 | 118,719 | 147,703 |
| Short-term investments | US$ in thousands | 480,224 | 217,630 | 128,599 | 622,203 | 220,310 |
| Receivables | US$ in thousands | — | — | — | — | — |
| Total current liabilities | US$ in thousands | 139,100 | 112,494 | 130,789 | 117,147 | 421,385 |
| Quick ratio | 4.29 | 2.99 | 2.77 | 6.32 | 0.87 |
December 31, 2024 calculation
Quick ratio = (Cash + Short-term investments + Receivables) ÷ Total current liabilities
= ($115,850K
+ $480,224K
+ $—K)
÷ $139,100K
= 4.29
The quick ratio of Halozyme Therapeutics Inc has shown significant fluctuations over the years as follows:
- In December 2020, the quick ratio was 0.87, indicating that the company had insufficient liquid assets to cover its current liabilities.
- By December 2021, the quick ratio surged to 6.32, suggesting a substantial improvement in the company's ability to meet its short-term obligations with its most liquid assets.
- In December 2022, the quick ratio decreased to 2.77, still demonstrating a healthy liquidity position but not as strong as the previous year.
- The quick ratio further increased to 2.99 by December 2023, showing continued stability in the company's ability to cover current liabilities with quick assets.
- Lastly, by December 2024, the quick ratio improved significantly to 4.29, indicating a strong liquidity position for Halozyme Therapeutics Inc, reflective of its ability to meet short-term obligations comfortably.
Overall, the trend in the quick ratio suggests that the company has been able to enhance its liquidity position over the years, with occasional fluctuations, but maintaining a healthy ability to cover short-term commitments with its liquid assets.
Peer comparison
Dec 31, 2024